Central diabetes insipidus following COVID-19 mRNA vaccination: a case report
- Author:
Min-Young KIM
1
;
Jong Ryeal HAHM
;
Jaehoon JUNG
;
Jung Hwa JUNG
;
Kyoung Young KIM
;
Hosu KIM
;
Jong Ha BAEK
;
Hwa Seon SHIN
;
Kee Ryeon KANG
;
Soo Kyoung KIM
Author Information
- Publication Type:Case report
- From:Kosin Medical Journal 2023;38(3):219-223
- CountryRepublic of Korea
- Language:English
- Abstract: The coronavirus disease 2019 (COVID-19) has been a major public health emergency worldwide. Vaccines were rapidly developed and approved to prevent the spread of viral infection. However, various side effects of the COVID-19 messenger RNA (mRNA) vaccines have been reported after their commercialization. A 24-year-old man visited our emergency department with polyuria and polydipsia that occurred after he received a COVID-19 mRNA vaccine 10 days beforehand. The initial laboratory findings showed very low urine osmolality with hyperosmolar hypernatremia. Based on these findings, diabetes insipidus was suspected, and sella magnetic resonance imaging showed an enlarged pituitary gland and the absence of posterior pituitary higher intensity. After 12 hours of using oral desmopressin acetate, urine volume decreased, and after 5 days of administration, serum electrolyte and serum osmolality improved. This case report of diabetes insipidus occurring after vaccination with the BNT162b2 mRNA COVID-19 vaccine is presented as a reminder that close monitoring is necessary for patients with polyuria and polydipsia after vaccination.
